Zusammenfassung
Die vorliegende Arbeit beschreibt den Verlauf von kognitiven und nicht kognitiven Symptomen bei Patienten mit Alzheimer-Demenz unter konstanten Behandlungsbedingungen mit einem Azetylcholinesterase-Inhibitor (Rivastigmin) und untersucht Zusammenhänge zwischen kognitiver Beeinträchtigung und nicht kognitiven Symptomen der Erkrankung. Von ursprünglich 91 Patienten konnten bei 44 Patienten mit leicht bis mäßig ausgeprägter Alzheimer-Demenz über den gesamten 2-Jahres-Zeitraum die globale funktionelle Beeinträchtigung (GDS), der kognitive Status (MMSE, ADAS-kog) und Verhaltensauffälligkeiten sowie psychopathologische Symptome (Behave-AD) erhoben werden. Dabei kam es unter der Therapie nach einer Stabilisierung der kognitiven Symptome über den Zeitraum von einem Jahr zu einer langsam voranschreitenden kognitiven Verschlechterung, während die psychopathologischen Phänomene auch nach 2 Jahren noch eine tendenzielle Besserung erkennen ließen und die wahnhafte Symptomatik sogar signifikant abnahm. In der durchgeführten Faktorenanalyse stellten kognitive Störungen als Kernsymptom der Alzheimer-Demenz über den gesamten Krankheitsverlauf einen konstanten Faktor dar und korrelierten mit der globalen Funktionsbeeinträchtigung. Psychopathologische Phänomene zeigten während der Erkrankung eine höhere Variabilität, wobei sich sowohl affektive Störungen in Kombination mit aggressivem Verhalten als auch halluzinatorische Phänomene im Verlauf als annähernd eigenständige Faktoren präsentierten. Damit konnte ergänzend zu anderen Verlaufsuntersuchungen erstmalig auch an Alzheimer-Patienten, die konstant mit einem Azetylcholinesterase-Inhibitor (Rivastigmin) behandelt wurden, gezeigt werden, dass bestimmte psychopathologische Phänomene eigenständige Faktoren im Krankheitsverlauf darstellen können.
Abstract
The course of behavioural and psychotic features of patients with Alzheimer's disease treated with an inhibitor of the acetylcholinesterase (rivastigmine), and their association to cognitive impairment is presented in the study. Standardized examination of global functional deterioration (GDS), cognitive impairment (MMSE) and behavioural or psychotic symptoms (Behave-AD) were performed over two years. We could analyse the complete data from 44 of initially 91 patients with mild to moderate Alzheimer's disease. The cognitive component (measured by MMSE, ADAS-cog) and the functional assessment (GDS) showed a continuous decline after a one year period of stabilization, in contrast with behavioural and psychotic symptoms, especially delusions, which still improved after treatment of two years. While cognitive items in correlation with functional aspects formed a homogenous factor over the two-year period, psychotic features displayed more variability over time evaluated by factor analysis. Nevertheless mood and anxiety disorder in combination with aggressive behaviour as well as hallucinations formed an independent factor in the course of Alzheimer's disease. In addition to other studies of the course of Alzheimer's disease we could demonstrate that distinct behavioural and psychotic symptoms may also present as independent factors in Alzheimer patients under constant treatment conditions with an inhibitor of the acetylcholinesterase (rivastigmine).
Literatur
1
Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M.
Occurrence and Progression of Dementia in a Community Population Aged 75 Years and Older.
Arch Neurol.
1999;
56
991-996
2
Wernicke T F, Reischies F M.
Prevalence of dementia in old age: Clinical diagnosis in subjects aged 95 years and older.
Neurology.
1994;
44
250-253
3
Mega M S, Cummings J L, Fiorello T, Gornbein J.
The spectrum of behavioral changes in Alzheimer's disease.
Neurology.
1996;
46
130-135
4
Drevets W C, Rubin E H.
Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type.
Biol Psychiatry.
1989;
25
39-48
5
Rosen J, Zubenko G S.
Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease.
Biol Psychiatry.
1991;
29
224-232
6
Haupt M, Romero B, Kurz A.
Delusions and hallucinations in Alzheimer's disease: results from a two-year longitudinal study.
Int J Geriatr Psychiat.
1996;
11
965-972
7
Devanand D P, Jacobs D M, Tang M X, Del Castillo-Castaneda C, Sano M, Marder K, Bell K, Bylsma F W, Brandt J, Albert M, Stern Y.
The course of psychopathologic features in mild to moderate Alzheimer disease.
Arch Gen Psychiatry.
1997;
54
257-263
8
Haupt M, Jänner M, Ebeling S, Stierstorfer A, Kretschmar C.
Presentation and stability of noncognitive symptom patterns in patients with Alzheimer's disease.
Alz Dis Ass Dis.
1998;
12
323-329
9
Steele C, Rovner B, Chase G A, Folstein M.
Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease.
Am J Psychiatry.
1990;
147
1049-1051
10
Haupt M, Kurz A.
Predictors of nursing home placement in patients with Alzheimer's disease.
Int J Geriatr Psychiat.
1993;
8
741-746
11
Knapp M J, Knopman D S, Solomon P R.
A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease.
JAMA.
1994;
271
985-991
12
Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller H J, Rogers S L, Friedhoff L T.
The effects of donezepil in Alzheimer's disease - results from a multinational trial.
Dement Geriatr Cogn Disord.
1999;
10
237-244
13
Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin H B, Hartman R, Gharabawi M.
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
BMJ.
1999;
318
633-638
14
Wilcock G K, Lilienfeld S, Gaens E.
Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial.
BMJ.
2000;
321
1-7
15
Kaufer D, Cummings J L, Christine D.
Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity.
Neuropsychiatry Clin Neurosci.
1998;
10
55-63
16
Rösler M, Retz W, Retz-Junginger P, Dennler H J.
Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease.
Behav Neurology.
1998/1999;
11
211-216
17
Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm A L, Zhang R, Haglund A, Subbiah P.
A 1-year, randomised, placebo-controlled study of donezepil in patients with mild to moderate AD.
Neurology.
2001;
57
489-495
18
Mc Khann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E M.
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease.
Neurology.
1984;
34
936-944
19
Folstein M F, Folstein S E, McHugh P R.
“Mini Mental State”. A practical method for grading the cognitive state of patients for the clinician.
J Psychiatric Res.
1975;
12
1-22
20 Mohs R C, Rosen W G, Davis K L. Defining treatment efficacy in patient with Alzheimer's disease: A report of progress in research. Edited by Corkin S, Davis KL, Growdon JH et al. New York: Raven Press 1982
21
Reisberg B, Borenstein J, Salob S P, Ferris S H, Franssen E, Georgotas A.
Behavioral symptoms in Alzheimer's disease: phenomenology and treatment.
J Clin Psychiatry.
1987;
48 (Suppl. 5)
9-15
22
Reisberg B, Ferris S, de Leon M, Crook T.
Global Deterioration Scale (GDS).
Psychopharmacol Bull.
1988;
24
661-663
23
Birkett D P.
The psychiatric differentation of senility and arteriosclerosis.
Br J Psychiatry.
1972;
120
321-325
24
Leuchter A F, Spar J E.
The late onset psychoses.
J Nerv Ment Disord.
1985;
173
488-494
25
Ballard C, Oyebode F.
Psychotic symptoms in patients with dementia.
Int J Geriatr Psychiat.
1995;
10
743-752
26
Cummings J L, Miller B, Hill M A, Neshres R.
Neuropsychiatric aspects of multi-infarct dementia and dementia of the Alzheimer-type.
Arch Neurol.
1987;
44
389-393
27
Rabins P V, Mace N L, Lucas M J.
The impact of dementia on the family.
J Am Med Assoc.
1982;
248
333-335
28
Wragg R, Jeste D.
Overview of depression and psychosis in Alzheimer's disease.
Am J Psychiatry.
1988;
146
577-587
29
Gormley N, Rizwan M R, Lovestone S.
Clinical predictors of aggressive behaviour in Alzheimer's disease.
Int J Geriatr Psychiat.
1998;
13
109-115
30
Keene J, Hope T, Fairburn C G, Jacoby R, Gedling K, Ware C JG.
Natural history of aggressive behaviour in dementia.
Int J Geriat Psychiatry.
1999;
14
541-548
31
Borson S, Raskind M A.
Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease.
Neurology.
1997;
48 (Suppl. 6)
S17-S24
32
Farlow M, Anand R, Messina Jr J, Hartmann R, Veach J.
A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.
Eur Neurol.
2000;
44
236-241
33
Rogers S L, Friedhoff L T.
Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the result of a US multicentre open label extension study.
Eur Neuropsychopharmacol.
1998;
8
67-75
34
Weiner M F, Martin-Cock K, Forster B M, Saine K, Fontaine C S, Svetlik D A.
Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients.
J Clin Psychiatry.
2000;
61
487-492
35
Rösler M.
The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
Int J Clin Pract.
2002;
Supplement 127
20-36
36
Migliorelli E, Teson A, Sabe L, Petracchi M, Leiguarda R, Starkstein S E.
Prevalence and correlates of dysthymia and major depression among patients with Alzheimer's disease.
Am J Psychiatry.
1995;
152
37-44
37
Haupt M, Kurz A, Jänner M.
A 2-year follow-up of behavioural and psychological symptoms in Alzheimer's disease.
Dement Geriatr Cogn Disord.
2000;
11
147-152
38
Hope T, Keene J, Fairburn C G, Jacoby R, McShane R.
Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease.
Br J Psychiatry.
1999;
174
39-44
39
Burns A, Jacoby R, Levy R.
Psychiatric phenomena in Alzheimer's disease. II: Disorders of perception.
Br J Psychiatry.
1990;
157
76-81
40
Förstl H, Besthorn C, Geiger-Kabisch C, Sattel H, Schreiter-Gasser U.
Psychotic features and the course of Alzheimer's disease: relationship to cognitive, electroencephalographic and computerized tomography findings.
Acta Psychiatr Scand.
1993;
87
395-399
41
Patel V, Hope T.
Aggessive behaviour in elderly people with dementia: a review.
Int J Geriatr Psychiatry.
1993;
8
457-472
42
Burns A, Jacoby R, Levy R.
Psychiatric phenomena in Alzheimer's disease. IV: Disorders of behaviour.
Br J Psychiatry.
1990;
157
86-94
Dr. med. T. Wobrock
Universitäts-Nervenklinik und Poliklinik · Psychiatrie und Psychotherapie
66421 Homburg/Saar
eMail: thomas.wobrock@uniklinik-saarland.de